Eli Lilly Collaborating With EVA Pharma to Expand Access to Baricitinib in African Countries

MT Newswires Live09-04

Eli Lilly and Company (LLY) and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in Africa by 2030 to treat of various immunological diseases.

Lilly said it will license certain baricitinib manufacturing knowledge to allow EVA Pharma to manufacture and supply the treatment for rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.

EVA Pharma's dedicated high-containment facility is expected to start sales of the locally manufactured baricitinib by 2026 to various African countries, the companies said.

Price: 946.52, Change: -10.01, Percent Change: -1.05

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2464373447?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-04 19:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2464373447","market":"nz","top_or_hot":-1,"title":"Eli Lilly Collaborating With EVA Pharma to Expand Access to Baricitinib in African Countries","media":"MT Newswires Live","content":"<html><body><p> Eli Lilly and Company (LLY) and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in Africa by 2030 to treat of various immunological diseases.</p><p>Lilly said it will license certain baricitinib manufacturing knowledge to allow EVA Pharma to manufacture and supply the treatment for rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.</p><p>EVA Pharma's dedicated high-containment facility is expected to start sales of the locally manufactured baricitinib by 2026 to various African countries, the companies said.</p><p>Price: 946.52, Change: -10.01, Percent Change: -1.05</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Collaborating With EVA Pharma to Expand Access to Baricitinib in African Countries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Collaborating With EVA Pharma to Expand Access to Baricitinib in African Countries\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-04 19:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly and Company (LLY) and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2464373447","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2464373447","pubTimestamp":1725448896,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eli Lilly and Company  and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in Africa by 2030 to treat of various immunological diseases.Lilly said it will license certain baricitinib manufacturing knowledge to allow EVA Pharma to manufacture and supply the treatment for rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.EVA Pharma's dedicated high-containment facility is expected to start sales of the locally manufactured baricitinib by 2026 to various African countries, the companies said.Price: 946.52, Change: -10.01, Percent Change: -1.05","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来","EVA":"Enviva Partners, LP"},"translate_title":"礼来公司与EVA Pharma合作扩大Baricitinib在非洲国家的可及性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVA":1,"LLY":1},"content_text":"Eli Lilly and Company (LLY) and EVA Pharma said Wednesday that they have entered into an agreement to expand access to baricitinib to about 20,000 people across 49 low- to middle-income countries in Africa by 2030 to treat of various immunological diseases.Lilly said it will license certain baricitinib manufacturing knowledge to allow EVA Pharma to manufacture and supply the treatment for rheumatoid arthritis, alopecia areata, atopic dermatitis, and COVID-19.EVA Pharma's dedicated high-containment facility is expected to start sales of the locally manufactured baricitinib by 2026 to various African countries, the companies said.Price: 946.52, Change: -10.01, Percent Change: -1.05","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2464373447"}